Five Prime Therapeutics Newswire

Comprehensive Real-Time News Feed for Five Prime Therapeutics.

Results 1 - 20 of 36 in Five Prime Therapeutics

  1. Five Prime Therapeutics, Inc. To Announce Second Quarter Financial...Read the original story

    16 hrs ago | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its second quarter 2014 financial results on Tuesday, August 5, 2014, after the U.S. financial markets close.

    Comment?

  2. Five Prime Therapeutics to Announce Second Quarter Financial Results...Read the original story

    Tuesday | Hispanic Business

    The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at www.fiveprime.com .

    Comment?

  3. Roche Profit Dented by CurrenciesRead the original story w/Photo

    Wednesday Jul 23 | Wall Street Journal

    Roche Holding AG reported Thursday that first-half net profit slid 7% under pressure from exchange rates, but strong sales of its cancer therapies prompted the Swiss drug giant to confirm its outlook for the full year.

    Comment?

  4. Roche Profit Falls on Franc Strengthl New-Drug Sales RiseRead the original story

    Wednesday Jul 23 | Bloomberg

    Roche Holding AG 's first-half profit fell 7 percent as the strength of the Swiss franc offset rising sales of the drugmaker's new cancer medicines.

    Comment?

  5. Why Is Wall Street Gobbling Up These 2 Small-Cap Biotech Stocks?Read the original story

    Tuesday Jul 8 | The Motley Fool

    ... Five Prime's novel platform has attracted the attention of major pharmas The little-known biotech Five Prime Therapeutics is starting to garner attention from both Wall Street and Big Pharma alike. At its core, Five Prime's commercial prospects ...

    Comment?

  6. The Daily Startup: Large Russian Venture Fund Looks Elsewhere for InvestmentsRead the original story w/Photo

    Thursday Jul 3 | Wall Street Journal

    Runa Capital , a venture firm founded by entrepreneurs with strong Moscow ties, is raising a second venture fund that will haul in between $200 million and $300 million, Yuliya Chernova reports in VentureWire.

    Comment?

  7. The Daily Startup: Large Russian Venture Fund Looks Elsewhere for InvestmentsRead the original story w/Photo

    Thursday Jul 3 | Wall Street Journal

    Runa Capital , a venture firm founded by entrepreneurs with strong Moscow ties, is raising a second venture fund that will haul in between $200 million and $300 million, Yuliya Chernova reports in VentureWire.

    Comment?

  8. Roche Buys Private Biotech Seragon for Up to $1.7BRead the original story w/Photo

    Wednesday Jul 2 | Fox News

    Roche Holding AG said it would pay up to $1.725 billion to buy Seragon Pharmaceuticals, a privately-held U.S. biotech company that researches breast cancer treatments.

    Comment?

  9. Five Prime Therapeutics to Present at 2014 Wells Fargo Healthcare ConferenceRead the original story

    Jun 11, 2014 | GlobeNewswire

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Aron Knickerbocker, Chief Business Officer of Five Prime, will present at the 2014 Wells Fargo Healthcare Conference on Wednesday, June 18 at 1:50 PM ... (more)

    Comment?

  10. Roche Inks Deal for Genia TechnologiesRead the original story

    Jun 2, 2014 | TheStreet.com

    NEW YORK -- Switzerland's Roche Holding on Monday agreed to buy Genia Technologies in hopes the target's genetic sequencing technology may dramatically lower the price of identifying DNA while speeding sequencing.

    Comment?

  11. Roche Inks Deal for Genia TechnologiesRead the original story

    Jun 2, 2014 | TheStreet.com

    Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.

    Comment?

  12. Roche Buys U.S. DNA Sequencing FirmRead the original story

    Jun 2, 2014 | Wall Street Journal

    Roche Holding AG said Monday that it is acquiring a California company that develops DNA-sequencing technology as part of the Swiss pharmaceutical giant's push deeper into diagnostics.

    Comment?

  13. Roche Agrees to Buy Genia Technologies for Up to $350 MillionRead the original story

    Jun 2, 2014 | The Washington Post

    Roche Holding AG agreed to buy Genia Technologies Inc. for as much as $350 million as part of an expansion in the gene-sequencing market.

    Comment?

  14. Five Prime Therapeutics, Inc. To Present At Jefferies and Co. 2014 Global Healthcare ConferenceRead the original story

    May 29, 2014 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the Jefferies 2014 Global Healthcare ... (more)

    Comment?

  15. Roche receives orphan status for Myeloid Leukemia treatmentRead the original story

    May 23, 2014 | Theflyonthewall.com

    Roche says authorities visisted Chinese facilities this week, WSJ reports Roche says authorities visited its facilities in Hangzhou, China this week, the Wall Street Journal reports.

    Comment?

  16. Roche says authorities visisted Chinese facilities this week, WSJ reportsRead the original story

    May 12, 2014 | Theflyonthewall.com

    Roche says authorities visisted Chinese facilities this week, WSJ reports Roche says authorities visited its facilities in Hangzhou, China this week, the Wall Street Journal reports.

    Comment?

  17. Five Prime Therapeutics Inc Files (8-K) Disclosing Submission of...Read the original story

    May 20, 2014 | Hispanic Business

    The proposals set forth below are described in detail in FivePrime's definitive proxy statement filed with the Proposal 1: FivePrime's stockholders elected all of the nominees for Class I directors to serve a three-year term until the 2017 Annual Meeting, or until their respective successors are duly elected and qualified, by the votes set forth in ... (more)

    Comment?

  18. Genentech treatment granted orphan statusRead the original story

    May 2, 2014 | Theflyonthewall.com

    Genentech treatment granted orphan status Genentech's recombinant humanized monoclonal antibody of the immunoglobulin G1 subclass directed against colony stimulating factor-1 receptor expressed on macrophages was granted FDA orphan designation for the treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor, according to a ... (more)

    Comment?

  19. Celldex, Bristol-Myers Cut Deal on Immuno-Oncology Combo TrialRead the original story

    May 14, 2014 | The Motley Fool

    ... trials with other companies' drugs. Recently, for instance, Bristol-Myers cut a deal with Five Prime Therapeutics to develop more checkpoint inhibitors . The Celldex transaction gives Bristol-Myers another proverbial shot on goal. And just this ...

    Comment?

  20. 28 Stocks That Could Double in Two Years No Matter What the Market DoesRead the original story

    Apr 17, 2014 | SBWire

    ... on the low end (chipmaker Intel INTC +0.64%). A few list members - biotech names Dyax DYAX +2.56%, Five Prime Therapeutics and Rigel Pharmaceuticals RIGL +2.56% - aren't expected to be profitable." Instead of directly investing in stocks, many pro ...

    Comment?